Physician profile
Mark Lichtenberg
NPI 1457454266
$4,090.86
in general payments reported to CMS, 2019-2025
22 companies · $991 in 2025
The $991 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $249 · 2021: $186 · 2022: $902 · 2023: $335 · 2024: $693 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $458.72 | 2023-2025 | |
| Lilly USA, LLC | $446.22 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Leo Pharma INC. | $419.26 | 2019-2025 | Adbry |
| Genzyme Corporation | $417.52 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $404.20 | 2020-2023 | Dupixent |
| Pfizer INC. | $276.04 | 2019-2022 | |
| Galderma Laboratories, L.P. | $233.38 | 2019-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $214.44 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $192.79 | 2022-2023 | Sotyktu |
| Incyte Corporation | $183.91 | 2022-2025 | Opzelura, Opzelura |
| Ucb, INC. | $161.54 | 2024 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $154.97 | 2019-2020 | |
| Janssen Biotech, INC. | $146.24 | 2024 | Tremfya |
| Gilead Sciences, INC. | $104.32 | 2019-2020 | |
| Epi Health, LLC | $78.00 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $63.22 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $53.50 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $22.87 | 2019 | |
| Sandoz INC. | $19.30 | 2020 | |
| Biofrontera INC. | $15.00 | 2019 | |
| Paratek Pharmaceuticals, INC. | $12.76 | 2021 | |
| Amgen INC. | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lichtenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.